Program
HSK39297
A development code. Also written as “HSK39297 tablets”, “HSK39297 200mgQD” and “HSK39297 300mgQD”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA · Lupus Nephritis, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 105 open or running | phase 3since Jan 23, 2025 | Apr 1, 2024 | Dec 5, 2026phase 2 · NCT07616700 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 1, 2024First study: phase 1 study in HealthyFirst studyNCT06350279 · 96 enrolled · China
- Aug 16, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06561841 · 47 enrolled · China
- Oct 15, 2024Phase 2 study in Glomerulonephritis, IGANCT06670352 · 87 enrolled · China
- Dec 12, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06745622 · 47 planned · China
- Jan 23, 2025Phase 3 study in PNHNCT06799546 · 73 enrolled · China
- Jun 29, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT07052838 · 36 enrolled · China
- Aug 26, 2025Phase 1 study in Hemoglobinuria, ParoxysmalNCT07152288 · 24 planned · China
- Dec 3, 2025Phase 2 study in Lupus NephritisNCT07363460 · 105 planned · China
- Jan 29, 2026Phase 3 study in Glomerulonephritis, IGANCT07390123 · 370 planned · China
- Apr 7, 2026Phase 2 study in Glomerulonephritis, IGANCT07616700 · 73 planned · China
Ahead
- Dec 5, 2026Primary completion: phase 2 study in Glomerulonephritis, IGANCT07616700
- Jun 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06745622
- Nov 5, 2027Primary completion: phase 2 study in Lupus NephritisNCT07363460
- Dec 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT07390123
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07616700Glomerulonephritis, IGA · China | 2 | Recruiting | Dec 5, 2026 | 73 |
| NCT07390123Glomerulonephritis, IGA · China | 3 | Recruiting | Dec 2027 | 370 |
| NCT07363460Lupus Nephritis · China | 2 | Recruiting | Nov 5, 2027 | 105 |
| NCT07152288Hemoglobinuria, Paroxysmal · China | 1 | Recruiting | Sep 2025 | 24 |
| NCT07052838Hemoglobinuria, Paroxysmal · China | 3 | Completed | Dec 23, 2025 | 36 |
| NCT06799546PNH · China | 3 | Completed | Nov 5, 2025 | 73 |
| NCT06745622Hemoglobinuria, Paroxysmal · China | 2 | Recruiting | Jun 2027 | 47 |
| NCT06670352Glomerulonephritis, IGA · China | 2 | Completed | Dec 20, 2025 | 87 |
| NCT06561841Hemoglobinuria, Paroxysmal · China | 2 | Completed | Apr 2, 2025 | 47 |
| NCT06350279Healthy · China | 1 | Completed | Aug 2, 2024 | 96 |
How it is read
Names in the registry
- “HSK39297 tablets”, 6 entries
- “HSK39297 200mgQD”, 3 entries
- “HSK39297”, 3 entries
- “HSK39297 300mgQD”, 2 entries
- “HSK39297 50mgBID”, 1 entry
Codes read as this program: HSK39297.
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 4 studies
- Glomerulonephritis, IGA, 3 studies
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.